| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apoptosis | 20 | 2017 | 197 | 1.400 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2021 | 42 | 1.260 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 4 | 2023 | 20 | 1.180 |
Why?
|
| Proteinuria | 3 | 2019 | 49 | 1.180 |
Why?
|
| Reactive Oxygen Species | 11 | 2019 | 104 | 1.150 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2017 | 33 | 0.990 |
Why?
|
| Prostatic Neoplasms | 6 | 2016 | 92 | 0.940 |
Why?
|
| Mice | 24 | 2023 | 1247 | 0.780 |
Why?
|
| Animals | 28 | 2023 | 3289 | 0.770 |
Why?
|
| Withanolides | 2 | 2013 | 4 | 0.740 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2019 | 15 | 0.710 |
Why?
|
| Podocytes | 2 | 2019 | 36 | 0.690 |
Why?
|
| Biphenyl Compounds | 2 | 2014 | 5 | 0.690 |
Why?
|
| Lignans | 2 | 2014 | 6 | 0.690 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 37 | 0.650 |
Why?
|
| Ascorbic Acid | 8 | 2008 | 31 | 0.650 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2019 | 6 | 0.580 |
Why?
|
| Cell Line, Tumor | 16 | 2014 | 241 | 0.580 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 376 | 0.580 |
Why?
|
| Cell Cycle | 5 | 2009 | 33 | 0.580 |
Why?
|
| Cell Proliferation | 8 | 2017 | 165 | 0.550 |
Why?
|
| Allyl Compounds | 3 | 2014 | 6 | 0.550 |
Why?
|
| Antioxidants | 4 | 2014 | 56 | 0.530 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 121 | 0.530 |
Why?
|
| Transcription, Genetic | 3 | 2007 | 96 | 0.520 |
Why?
|
| Myeloid Cells | 1 | 2016 | 9 | 0.500 |
Why?
|
| Protein Disulfide-Isomerases | 2 | 2013 | 4 | 0.480 |
Why?
|
| Vasculitis | 2 | 2014 | 25 | 0.480 |
Why?
|
| Mice, Knockout | 8 | 2019 | 276 | 0.460 |
Why?
|
| Cytoprotection | 1 | 2014 | 9 | 0.420 |
Why?
|
| Autophagy | 1 | 2014 | 30 | 0.410 |
Why?
|
| Macrophage-1 Antigen | 2 | 2014 | 6 | 0.410 |
Why?
|
| Disulfides | 1 | 2014 | 10 | 0.410 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 197 | 0.410 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 15 | 0.410 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 4 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2013 | 17 | 0.390 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 8 | 0.390 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2023 | 9 | 0.340 |
Why?
|
| Humans | 33 | 2021 | 23144 | 0.340 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 36 | 0.340 |
Why?
|
| Transcription Factor AP-1 | 3 | 2005 | 16 | 0.320 |
Why?
|
| Melanoma, Experimental | 2 | 2007 | 4 | 0.320 |
Why?
|
| Down-Regulation | 7 | 2014 | 87 | 0.290 |
Why?
|
| Mice, Transgenic | 3 | 2023 | 178 | 0.270 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 5 | 0.270 |
Why?
|
| Curcumin | 2 | 2004 | 6 | 0.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 8 | 0.260 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 11 | 0.260 |
Why?
|
| Signal Transduction | 10 | 2017 | 386 | 0.250 |
Why?
|
| Apolipoprotein C-III | 3 | 2023 | 6 | 0.250 |
Why?
|
| Inflammasomes | 2 | 2023 | 11 | 0.230 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 3 | 2011 | 7 | 0.220 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2011 | 11 | 0.220 |
Why?
|
| Neutrophils | 3 | 2014 | 89 | 0.210 |
Why?
|
| Phosphorylation | 5 | 2013 | 130 | 0.210 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 16 | 0.210 |
Why?
|
| Caspases | 6 | 2007 | 22 | 0.210 |
Why?
|
| Superoxide Dismutase | 3 | 2013 | 18 | 0.200 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2017 | 14 | 0.200 |
Why?
|
| Anticarcinogenic Agents | 2 | 2016 | 18 | 0.190 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 526 | 0.190 |
Why?
|
| Mitochondria | 4 | 2009 | 55 | 0.180 |
Why?
|
| Sepsis | 1 | 2023 | 76 | 0.180 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 75 | 0.180 |
Why?
|
| Blood Platelets | 2 | 2013 | 35 | 0.180 |
Why?
|
| Caspase 8 | 3 | 2019 | 10 | 0.180 |
Why?
|
| Vascular System Injuries | 1 | 2021 | 5 | 0.180 |
Why?
|
| Neoplasms | 1 | 2004 | 220 | 0.180 |
Why?
|
| Kidney | 3 | 2021 | 146 | 0.170 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2014 | 5 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 13 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 48 | 0.170 |
Why?
|
| Inflammation | 3 | 2023 | 233 | 0.160 |
Why?
|
| NF-kappa B | 3 | 2005 | 100 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 125 | 0.160 |
Why?
|
| Blotting, Western | 4 | 2016 | 126 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 2 | 2019 | 90 | 0.160 |
Why?
|
| Interleukin-18 | 3 | 2004 | 8 | 0.150 |
Why?
|
| Monocytes | 1 | 2019 | 38 | 0.150 |
Why?
|
| Male | 10 | 2017 | 12609 | 0.150 |
Why?
|
| Biomarkers | 2 | 2023 | 488 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 6 | 2016 | 124 | 0.150 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 19 | 0.150 |
Why?
|
| Cell Survival | 4 | 2014 | 97 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 69 | 0.150 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 298 | 0.140 |
Why?
|
| Isothiocyanates | 2 | 2016 | 5 | 0.140 |
Why?
|
| Sulfides | 2 | 2009 | 10 | 0.140 |
Why?
|
| Melanoma | 3 | 2008 | 49 | 0.130 |
Why?
|
| G1 Phase | 2 | 2007 | 16 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 67 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2007 | 22 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2005 | 51 | 0.130 |
Why?
|
| Apolipoproteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Drosophila Proteins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 23 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2013 | 35 | 0.130 |
Why?
|
| Pyridines | 3 | 2013 | 27 | 0.130 |
Why?
|
| RNA, Messenger | 6 | 2016 | 274 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2013 | 460 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 72 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2016 | 41 | 0.120 |
Why?
|
| Imidazoles | 3 | 2013 | 62 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2007 | 85 | 0.120 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 32 | 0.120 |
Why?
|
| Kidney Glomerulus | 1 | 2016 | 40 | 0.120 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 51 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 6 | 0.120 |
Why?
|
| Protein Binding | 3 | 2013 | 112 | 0.120 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2013 | 26 | 0.120 |
Why?
|
| Adenosine Triphosphate | 2 | 2013 | 21 | 0.110 |
Why?
|
| Oleanolic Acid | 2 | 2005 | 6 | 0.110 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2005 | 23 | 0.110 |
Why?
|
| Enzyme Activation | 4 | 2008 | 109 | 0.110 |
Why?
|
| rho GTP-Binding Proteins | 2 | 2011 | 8 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 314 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 2 | 2005 | 32 | 0.100 |
Why?
|
| Anthracenes | 1 | 2013 | 4 | 0.100 |
Why?
|
| Flavonoids | 1 | 2013 | 15 | 0.100 |
Why?
|
| MCF-7 Cells | 1 | 2013 | 15 | 0.100 |
Why?
|
| RNA Interference | 1 | 2013 | 35 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 56 | 0.100 |
Why?
|
| Hemostasis | 1 | 2013 | 11 | 0.100 |
Why?
|
| Cyclooxygenase 2 | 3 | 2008 | 29 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2013 | 10 | 0.100 |
Why?
|
| Luciferases | 3 | 2007 | 25 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 14 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 30 | 0.100 |
Why?
|
| Ligands | 1 | 2013 | 32 | 0.100 |
Why?
|
| Immunoprecipitation | 3 | 2007 | 19 | 0.090 |
Why?
|
| Thrombosis | 1 | 2013 | 51 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 356 | 0.090 |
Why?
|
| Electron Transport Complex III | 1 | 2011 | 2 | 0.090 |
Why?
|
| Oxidative Phosphorylation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 11 | 0.090 |
Why?
|
| Protective Agents | 1 | 2011 | 7 | 0.090 |
Why?
|
| Rats | 1 | 2013 | 619 | 0.090 |
Why?
|
| Embryonic Stem Cells | 1 | 2011 | 10 | 0.080 |
Why?
|
| DNA | 3 | 2005 | 98 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 83 | 0.080 |
Why?
|
| Acetylcysteine | 2 | 2007 | 14 | 0.080 |
Why?
|
| fas Receptor | 2 | 2007 | 5 | 0.080 |
Why?
|
| Female | 3 | 2017 | 13096 | 0.080 |
Why?
|
| Thiocyanates | 1 | 2009 | 4 | 0.070 |
Why?
|
| Trans-Activators | 2 | 2005 | 21 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 10 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2013 | 48 | 0.070 |
Why?
|
| Arsenicals | 2 | 2005 | 11 | 0.070 |
Why?
|
| Oxides | 2 | 2005 | 13 | 0.070 |
Why?
|
| Cell Movement | 2 | 2006 | 75 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2007 | 8 | 0.070 |
Why?
|
| beta Catenin | 2 | 2005 | 58 | 0.070 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2007 | 3 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 7 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 105 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2007 | 16 | 0.070 |
Why?
|
| 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide | 1 | 2007 | 2 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 60 | 0.070 |
Why?
|
| Pregnenediones | 1 | 2007 | 3 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2007 | 9 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 19 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2005 | 149 | 0.060 |
Why?
|
| Insulin | 1 | 2007 | 77 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2019 | 140 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2004 | 224 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2007 | 83 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 537 | 0.060 |
Why?
|
| Liver | 1 | 2007 | 135 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 10 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 133 | 0.060 |
Why?
|
| Osteoclasts | 1 | 2005 | 20 | 0.060 |
Why?
|
| Receptors, Transferrin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Flavanones | 1 | 2005 | 2 | 0.060 |
Why?
|
| Iron | 1 | 2005 | 14 | 0.060 |
Why?
|
| Ionomycin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2005 | 27 | 0.060 |
Why?
|
| TCF Transcription Factors | 1 | 2005 | 11 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2005 | 5 | 0.050 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2004 | 7 | 0.050 |
Why?
|
| HL-60 Cells | 4 | 2005 | 11 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 56 | 0.050 |
Why?
|
| Umbilical Cord | 1 | 2004 | 3 | 0.050 |
Why?
|
| Chick Embryo | 1 | 2004 | 15 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2004 | 6 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2004 | 6 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2004 | 30 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 50 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 35 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 32 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2004 | 40 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 87 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 69 | 0.050 |
Why?
|
| E-Box Elements | 1 | 2004 | 2 | 0.050 |
Why?
|
| Microglia | 1 | 2004 | 108 | 0.050 |
Why?
|
| Sulfoxides | 2 | 2016 | 5 | 0.050 |
Why?
|
| Cell Line | 2 | 2019 | 244 | 0.050 |
Why?
|
| Keratinocytes | 1 | 2002 | 4 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2002 | 8 | 0.050 |
Why?
|
| Antigens, Surface | 1 | 2002 | 13 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 231 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 22 | 0.050 |
Why?
|
| Fibrosis | 1 | 2021 | 32 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 60 | 0.040 |
Why?
|
| Glutathione | 3 | 2005 | 23 | 0.040 |
Why?
|
| Hydrogen Peroxide | 3 | 2005 | 40 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 24 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 59 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 21 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2019 | 25 | 0.040 |
Why?
|
| Caspase 9 | 3 | 2004 | 8 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 100 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2017 | 3 | 0.030 |
Why?
|
| Apolipoprotein L1 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Drosophila melanogaster | 1 | 2017 | 11 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2009 | 17 | 0.030 |
Why?
|
| Transfection | 2 | 2009 | 115 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 172 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 264 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 29 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 33 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 277 | 0.030 |
Why?
|
| Enzyme Inhibitors | 2 | 2008 | 114 | 0.030 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2005 | 12 | 0.030 |
Why?
|
| Protein Subunits | 2 | 2005 | 16 | 0.030 |
Why?
|
| Talin | 1 | 2014 | 2 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cytochromes c | 2 | 2004 | 11 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 12 | 0.030 |
Why?
|
| Cell Communication | 1 | 2014 | 21 | 0.030 |
Why?
|
| Fibrin | 1 | 2013 | 4 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2013 | 6 | 0.020 |
Why?
|
| Shear Strength | 1 | 2013 | 7 | 0.020 |
Why?
|
| Kinetics | 2 | 2004 | 176 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 1460 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 124 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2013 | 60 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2014 | 119 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 1877 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 1655 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2011 | 4 | 0.020 |
Why?
|
| Pseudopodia | 1 | 2011 | 5 | 0.020 |
Why?
|
| Platelet Transfusion | 1 | 2011 | 6 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 2011 | 24 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2011 | 123 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 370 | 0.020 |
Why?
|
| Electron Transport | 1 | 2009 | 4 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 4 | 0.020 |
Why?
|
| Garlic | 1 | 2009 | 2 | 0.020 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2009 | 2 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2009 | 18 | 0.020 |
Why?
|
| Bronchi | 1 | 2009 | 10 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2009 | 40 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 53 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 50 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 67 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 70 | 0.020 |
Why?
|
| Vitamins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 21 | 0.020 |
Why?
|
| Commiphora | 1 | 2007 | 2 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2007 | 13 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 6 | 0.020 |
Why?
|
| Gluconeogenesis | 1 | 2007 | 3 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2007 | 4 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 13 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2006 | 24 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 51 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2006 | 96 | 0.020 |
Why?
|
| Adult | 1 | 2017 | 6945 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 30 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2005 | 3 | 0.010 |
Why?
|
| DNA Probes | 1 | 2005 | 7 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2005 | 11 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 13 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 7624 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 7944 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 100 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 67 | 0.010 |
Why?
|
| I-kappa B Kinase | 1 | 2005 | 5 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 70 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 29 | 0.010 |
Why?
|
| Titrimetry | 1 | 2004 | 3 | 0.010 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2004 | 5 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 31 | 0.010 |
Why?
|
| Tosylphenylalanyl Chloromethyl Ketone | 1 | 2004 | 2 | 0.010 |
Why?
|
| Superoxides | 1 | 2004 | 23 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 30 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 64 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 16 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2004 | 72 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 20 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 2004 | 2 | 0.010 |
Why?
|
| Masoprocol | 1 | 2004 | 4 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 4 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2004 | 14 | 0.010 |
Why?
|
| Dimerization | 1 | 2004 | 20 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2004 | 60 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 60 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2004 | 15 | 0.010 |
Why?
|
| Densitometry | 1 | 2003 | 8 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2004 | 43 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2004 | 80 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 329 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 163 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 27 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 9 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2003 | 167 | 0.010 |
Why?
|
| CD48 Antigen | 1 | 2002 | 2 | 0.010 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 2 | 0.010 |
Why?
|
| Trihexosylceramides | 1 | 2002 | 2 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2002 | 2 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2002 | 4 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2002 | 5 | 0.010 |
Why?
|
| Neprilysin | 1 | 2002 | 7 | 0.010 |
Why?
|
| CD40 Ligand | 1 | 2002 | 7 | 0.010 |
Why?
|
| CD40 Antigens | 1 | 2002 | 6 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 49 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 140 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1260 | 0.010 |
Why?
|